Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
INTERFERON EPSILON (IFNE1) AS A MARKER FOR TARGETED CANCER THERAPY
Document Type and Number:
WIPO Patent Application WO/2009/150491
Kind Code:
A3
Abstract:
Disclosed is a method of employing Interferon Epsilon (IFNEI) as a therapeutic response, prognostic, or pharmacodynamic marker for cancer chemotherapeutic treatment using cyclin dependent kinase (CDK) inhibitors. IFNEI transcript is upregulated when cancer cells are treated with CDK inhibitors. The disclosure also includes the method of measuring a level of IFNE 1 or IFNE 1 mRNA in a subject's tumor, blood or other tissues. An increased level of IFNEI in comparison with a control level can be used as an indicator that the CDK inhibitor has produced a therapeutic effect or an indicator that a tumor is sensitive to a CDK inhibitor.

Inventors:
SHANKAR SUNITA (US)
VED URVI (US)
SHARMA SOMESH (IN)
Application Number:
IB2008/052278
Publication Date:
January 19, 2012
Filing Date:
June 10, 2008
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
PIRAMAL LIFE SCIENCES LTD (IN)
SHANKAR SUNITA (US)
VED URVI (US)
SHARMA SOMESH (IN)
International Classes:
C12Q1/68; G01N33/53
Domestic Patent References:
WO2009150491A22009-12-17
Foreign References:
US20060204975A12006-09-14
US20030013162A12003-01-16
Other References:
MATSUOKA ET AL.: "Interferon-a-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p191nk4D and p21Cip1 in mouse macrophages.", ONCOGENE, vol. 16, no. 16, 1998, pages 2075 - 2086, XP008150577
MATSUMIYA ET AL.: "IFN-e Mediates TNF-a-Induced STAT1 Phosphorylation and Induction of Retinoic Acid-Inducible Gene-I in Human Cervical Cancer Cells.", J IMMUNOL, vol. 179, 2007, pages 4542 - 4549, XP008150578
MALUMBRES ET AL.: "TO CYCLE OR NOT TO CYCLE: A CRITICAL DECISION IN CANCER.", NAT REV CANCER., vol. 1, no. 3, 2001, pages 222 - 231, XP008150580
See also references of EP 2307561A4
Download PDF: